Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2022-08-10 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
向不特定对象发行可转换公司债券预案
Capital/Financing Update Classification · 95% confidence The document is a detailed proposal and explanatory note for the issuance of convertible corporate bonds by Walvax Biotechnology Co., Ltd. It includes extensive information about the bond issuance plan, legal compliance, bond terms, conversion price adjustments, redemption and repurchase clauses, bondholder rights and obligations, and the intended use of the raised funds. Additionally, it contains comprehensive financial statements including balance sheets, income statements, and cash flow statements for multiple years, with audited data referenced. The document is lengthy (15,000 characters) and contains substantive financial data and management discussion related to the bond issuance. This is not a simple announcement or a brief summary but a full detailed issuance plan with financials. The content aligns with a Capital/Financing Update, as it focuses on the company's fundraising activity through convertible bonds and related financial and legal details. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-08-10 Chinese
关于向不特定对象发行可转换公司债券预案披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (639 characters) regarding the company's plan to issue convertible bonds to unspecified investors. It mentions the board meeting approval and disclosure of the issuance plan on a regulatory website. It explicitly states that this announcement is a "提示性公告" (indicative announcement) about the issuance plan, not the issuance itself or detailed financial data. The document does not contain financial statements or detailed analysis but serves as a notification of a capital raising plan. Therefore, it fits the category of Capital/Financing Update (CAP).
2022-08-10 Chinese
关于调整子公司玉溪沃森生物技术有限公司多糖结合疫苗扩产扩能项目的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Yunnan Watson Biotechnology Co., Ltd. regarding adjustments to a subsidiary's vaccine production capacity expansion project. It details the project background, changes, reasons, and impact on the company. There are no financial statements, earnings data, or detailed financial analysis. The document is a corporate announcement about a project adjustment, not a financial report or regulatory filing. It is also not a report publication announcement since it contains substantive information about the project adjustment itself. The content fits best under a general regulatory announcement category that covers miscellaneous corporate disclosures that do not fit other specific categories.
2022-08-10 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled '云南沃森生物技术股份有限公司2022 年半年度报告摘要' which translates to 'Yunnan Walvax Biotechnology Co., Ltd. 2022 Semi-Annual Report Summary'. It contains detailed financial data for the first half of 2022, including revenue, net profit, earnings per share, and asset information. It also discusses operational highlights, product sales, production, R&D progress, international business, and share repurchase activities. The document is about 7,793 characters long, which is substantial and contains actual financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a summary but contains substantive financial and operational information for the half-year period. H1 2022
2022-08-10 Chinese
未来三年（2022年—2024年）股东回报规划
Regulatory Filings Classification · 95% confidence The document is a detailed plan outlining the company's shareholder return policy for the next three years (2022-2024), focusing on dividend distribution principles, cash and stock dividends, decision-making procedures, and shareholder communication. It is a policy document related to dividends and shareholder returns rather than an announcement of dividend amounts or payment dates. It does not contain financial statements or earnings data, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a simple announcement of dividend amounts (which would be DIV), but a comprehensive policy plan. Therefore, the document best fits the category of a Regulatory Filing (RNS) as it is a regulatory disclosure of the company's dividend policy and shareholder return plan, which does not neatly fit into other specific categories.
2022-08-10 Chinese
可转换公司债券持有人会议规则
Governance Information Classification · 95% confidence The document is titled as "云南沃森生物技术股份有限公司 可转换公司债券持有人会议规则" which translates to "Rules for Convertible Bondholders' Meeting of Yunnan Watson Biotechnology Co., Ltd." The content details the organization, rights, obligations, procedures, and powers of the bondholders' meeting related to convertible bonds issued by the company. It includes legal references, meeting convening rules, voting procedures, and other governance aspects related to bondholder meetings. There is no indication that this is a financial report, earnings release, or announcement of voting results. Instead, it is a governance document outlining internal rules and procedures for bondholder meetings. Therefore, the most appropriate classification is Governance Information (CGR). The document length (8423 characters) and detailed procedural content support this classification with high confidence.
2022-08-10 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.